HomeCompareKKPCF vs MRK

KKPCF vs MRK: Dividend Comparison 2026

KKPCF yields 4.58% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KKPCF wins by $3.6K in total portfolio value
10 years
KKPCF
KKPCF
● Live price
4.58%
Share price
$26.00
Annual div
$1.19
5Y div CAGR
25.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$60.4K
Annual income
$10,901.81
Full KKPCF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — KKPCF vs MRK

📍 KKPCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKKPCFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KKPCF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KKPCF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KKPCF
Annual income on $10K today (after 15% tax)
$389.04/yr
After 10yr DRIP, annual income (after tax)
$9,266.54/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, KKPCF beats the other by $938.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KKPCF + MRK for your $10,000?

KKPCF: 50%MRK: 50%
100% MRK50/50100% KKPCF
Portfolio after 10yr
$58.6K
Annual income
$10,349.97/yr
Blended yield
17.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

KKPCF
No analyst data
Altman Z
4.9
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KKPCF buys
0
MRK buys
0
No recent congressional trades found for KKPCF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKKPCFMRK
Forward yield4.58%2.76%
Annual dividend / share$1.19$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR25.2%32.7%
Portfolio after 10y$60.4K$56.8K
Annual income after 10y$10,901.81$9,798.13
Total dividends collected$34.9K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KKPCF vs MRK ($10,000, DRIP)

YearKKPCF PortfolioKKPCF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,273$573.03$11,206$366.19+$67.00KKPCF
2$12,818$755.86$12,650$502.35+$168.00KKPCF
3$14,721$1,005.63$14,407$694.19+$314.00KKPCF
4$17,103$1,351.37$16,585$967.82+$518.00KKPCF
5$20,137$1,837.07$19,342$1,363.89+$795.00KKPCF
6$24,077$2,530.90$22,913$1,947.19+$1.2KKKPCF
7$29,304$3,540.89$27,662$2,823.89+$1.6KKKPCF
8$36,398$5,042.49$34,159$4,173.35+$2.2KKKPCF
9$46,274$7,328.49$43,337$6,308.80+$2.9KKKPCF
10$60,415$10,901.81$56,776$9,798.13+$3.6KKKPCF

KKPCF vs MRK: Complete Analysis 2026

KKPCFStock

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

Full KKPCF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this KKPCF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KKPCF vs SCHDKKPCF vs JEPIKKPCF vs OKKPCF vs KOKKPCF vs MAINKKPCF vs JNJKKPCF vs ABBVKKPCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.